Roche has entered into an exclusive agreement with PathAI, a global leader in artificial intelligence (AI) for pathology, to collaborate on developing AI-enabled digital pathology algorithms for Roche Tissue Diagnostics’ (RTD) companion diagnostics business. PathAI will be the sole external algorithm development company for AI-powered companion diagnostics during a pre-specified term, with the flexibility for RTD to continue developing its own algorithms. This collaboration aims to accelerate innovation in personalized healthcare, offering a powerful end-to-end solution for biopharma companies seeking AI-enabled companion diagnostics.
The developed algorithms will be deployed on Roche’s navify Digital Pathology platform, facilitating seamless integration into pathology laboratories worldwide. This partnership aligns with Roche’s commitment to advancing precision medicine, combining AI-interpretation and companion diagnostics to enhance patient access to targeted treatments.
Jill German, Head of Roche Tissue Diagnostics, expressed the company’s dedication to bringing new innovations to personalized healthcare. The collaboration with PathAI is expected to expedite the development of AI-enabled companion diagnostics, contributing to precision therapeutics.
Dr. Andy Beck, CEO and Co-Founder of PathAI, highlighted the shared commitment to advancing digital pathology and AI-enabled diagnostics for both drug development and clinical care. The collaboration builds on a previous agreement where the companies jointly developed an embedded image analysis workflow, integrating PathAI algorithms into Roche’s navify Digital Pathology software platform.
This collaboration reflects Roche’s leadership in companion diagnostics, contributing to the evolution of digital pathology as a standard in diagnosis and biomarker characterization. The companies’ efforts aim to provide high medical value diagnostic products with seamless integration into laboratory workflows, ultimately supporting clinicians in making accurate treatment decisions. Roche, as a pioneer in personalized healthcare and biotechnology, continues to pursue scientific excellence, emphasizing sustainability and improved global access to healthcare.